Can therapeutic efficacy be predicted from phase I data?

Summary— The aim of phase I studies per se is to explore the tolerance of new compounds which have demonstrated a certain level of activity in animals at sufficiently low non-toxic doses. In most cases, these studies are conducted in 2 steps in a limited number of healthy male volunteers: a single rising dose study followed by a repeated dose study in which the pharmacokinetic features of the drug are explored. In such a context, it would be quite presumptuous to ascertain the therapeutic efficacy of a drug from those initial human studies. At best, these trials can provide pharmacological and/or biological indications which are related to some degree to the expected efficacy of the drug: hypnotics, anticancer drugs, antibiotics, platelet antiaggregants, beta-blockers, etc. In these examples it is recommended to design controlled study protocols so as to better investigate these potentially interesting signs of activity. In the majority of cases, however (psychoactive drugs, analgesic, anti-inflammatory drugs, gastro-intestinal compounds), phase I studies will unfortunately not provide much information regarding the expected therapeutic activity.     

Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency

We treated patients with idiopathic membranous nephropathy (iMGN) and renal insufficiency, using: (i) (n = 15) monthly cycles of steroids (1 g methyl-prednisolone i.v. on three consecutive days, followed by oral prednisone 0.5 mg/kg/day months 1, 3 and 5) and chlorambucil (0.15 mg/kg/day months 2, 4 and 6); or (ii) (n = 17) oral cyclophosphamide (1.5-2.0 mg/kg/day for 1 year) and steroids in a comparable dose. The groups were comparable in age, renal function and levels of proteinuria. During the 6 months preceding treatment, serum creatinine levels increased from 148 +/- 50 to 219 +/- 73 mumol/l in the chlorambucil group and from 164 +/- 86 to 274 +/- 126 mumol/l in the cyclophosphamide group. Median (range) follow-ups were: chlorambucil 38 months (8-71); cyclophosphamide 26 months (5-68) (NS). Renal function improved in both groups, but the improvement was short-lived in the chlorambucil group; 12 months after starting treatment, mean serum creatinine was 6.3 mumol/l lower in the chlorambucil group and 121 mumol/l lower in the cyclophosphamide group (p < 0.01). Four chlorambucil-treated patients developed ESRD, and five needed a second course of therapy, whereas only one cyclophosphamide-treated patient developed ESRD (p < 0.05). Remissions of proteinuria occurred more frequently after cyclophosphamide treatment (15/17 vs. 5/15; p < 0.01). Side-effects necessitated interruption of treatment in six patients on cyclophosphamide and in 11 on chlorambucil (p < 0.05). In our patients, oral cyclophosphamide was better tolerated than oral chlorambucil. The suggested greater efficacy of the oral cyclophosphamide regimen needs to be ascertained by longer follow-up.      

Press Review

Diversion of Initial Blood Flow to prevent Whole Blood Contamination by Skin-Surface Bacteria: An in vitro Model     

Lymphome non hodgkinien Ki-1 positif révélé par des ulcérations cutanéomuqueuses et une glomérulonéphrite

Malignant lymphoma particularly of T phenotype can be associated with specific or non specific cutaneous lesions. These cutaneous manifestations can occur at the onset of the disease being sometimes the revealing sign or they can appear during the course of the lymphoreticular malignancies. Glomerulonephritis was also described in lymphoma. Ki- positive large cell lymphoma was recently identified. A new case is reported with lymphadenopathy and intestinal localisation revealed by cutaneous and mucosal ulcerations principally in the mouth and a focal segmental glomerulonephritis with endo- and extracapillary proliferation. The absence of lymphoma in cutaneous and renal lesions and the clinical presentation support the hypothesis of paraneoplastic manifestations, may be related to a vasculitis.     

颈动脉血管重构特征在自发性高血压大鼠体内的表现

目的:血管重构是高血压的重要病理变化,是高血压导致器官损害的结构基础。实验观察自发性高血压大鼠颈动脉中层组织学的相关变化,以验证血管重构的特点。方法:实验于2006-06/2007-03在福建医科大学附属协和医院心血管内科实验室完成。①实验材料及分组:12周龄雄性自发性高血压大鼠10只,同性别周龄的WKY大鼠10只为对照,喂养18周后终止实验。②实验过程及评估:开始及每2周测鼠尾收缩压。实验结束后,麻醉后取颈动脉,行苏木精-伊红、苦味酸-天狼星红、弹力纤维和胶原纤维的双重染色(P/VB法),利用计算机辅助成像系统测算颈动脉中膜厚度、腔径、血管中膜厚/腔径、中膜横截面积、中膜细胞平均核面积及中膜的胶原面积百分比、弹性纤维面积百分比、弹性纤维面积与胶原面积的比值。SP免疫组织化学染色检测α-平滑肌肌动蛋白、增殖细胞核抗原、纤维粘连蛋白、层粘连蛋白等抗原在颈动脉壁的表达,并计算颈动脉中膜细胞增殖指数;以原位末端标记法标记血管壁的凋亡细胞,计算颈动脉中膜细胞凋亡指数。结果:20只大鼠全部进入结果分析。①自发性高血压大鼠实验开始和结束前的收缩压均>150mmHg,高于WKY大鼠(P<0.01)。②自发性高血压大鼠颈动脉中膜厚度、腔径、中膜厚度/腔径、中膜横截面积、中膜胶原面积百分比均高于WKY大鼠(P<0.01),而中膜弹性纤维面积百分比、弹性纤维面积与胶原面积比值均低于WKY大鼠(P<0.01)。③α-平滑肌肌动蛋白在两组大鼠颈动脉中膜均可表达,提示中膜细胞为血管平滑肌细胞。④自发性高血压大鼠中膜血管平滑肌细胞平均核面积大于WKY大鼠(P<0.01),中膜细胞增殖指数与WKY大鼠差异无显著性(P>0.05),中膜细胞凋亡指数显著低于WKY大鼠(P<0.01)。⑤自发性高血压大鼠颈动脉中膜纤维粘连蛋白、层粘连蛋白的光密度值(IA值)及染色阳性面积百分比高于WKY大鼠(P<0.01)。⑥颈动脉中膜血管平滑肌细胞凋亡指数与中膜横截面积呈显著负相关(r=-0.872,P<0.01);纤维连接蛋白表达的吸光度值与中膜横截面积呈显著正相关(r=0.954,P<0.01)。结论:自发性高血压大鼠颈动脉存在明显的重构,其特点为中膜肥厚、平滑肌细胞肥大、凋亡减少及胶原、纤维粘连蛋白、层粘连蛋白的过度沉积。     

Can every patient be mobilized?

There are several ways to mobilize hematopoietic stem cells for autologous and allogeneic hematopoietic stem cell transplant by manipulating the bone marrow microenvironment. Granulocyte colony-stimulating factor (G-CSF) and chemotherapy have been commonly used to mobilize stem cells, but several new agents, such as the CXCR4 inhibitor plerixafor, inhibit stromal-stem cell interactions to improve stem cell yield. The minimum threshold for engraftment is 2 × 10? CD34+ cells/kg, but it has been shown that higher CD34+ stem cell dose, such as 5 × 10? CD34+ cells/kg, is associated with improved survival. Efforts to increase stem cell yield remain important to improve outcomes.     

Emergence of resistant Acinetobacter baumannii in critically ill patients within an acute care teaching hospital and a long-term acute care hospital

BACKGROUND: Acinetobacter baumannii is a gram-negative, coccobacillus found in water and is a significant nosocomial pathogen in hospitals. This report chronicles the appearance in June 2003 of a multidrug-resistant A baumannii (MDR-AB) strain, its dissemination, and interventions used to control it in an acute care hospital (ACH) and long-term acute care facility (LTAC). METHODS: Molecular typing using pulsed-field gel electrophoresis (PFGE) showed that 88 of 99 strains (89%) gave an identical banding designated as clone A. Eight additional isolates were variants of clone A, and 3 isolates were unrelated. RESULTS: A baumannii was isolated from 229 patients between January 2003 and December 2004. Of these patients, 151 (66%) were colonized/infected with MDR-AB. Most isolates were resistant to antibiotics except for imipenem and ampicillin/sulbactam. Isolates included 108 (72%) in the respiratory tract, 32 (21%) in wounds, 6 (4%) in blood, and 5 (3%) in urine. Most isolates were found in the LTAC (70 isolates), ICU step-down (27 isolates), and ICU (26 isolates). CONCLUSION: This epidemiologic history illustrates (1) epidemic clonal spread, (2) target populations, (3) variable monthly prevalence, and (4) intervention outcomes. With intervention, the number of new isolates in the ACH decreased by dedicating an infection control professional to critical care, daily surveillance, isolation of positive MDR-AB patients, universal gloving, and routinely reporting results.     

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications

Platelets have a central role in the development of arterial thrombosis and subsequent cardiovascular events. An appreciation of this complex process has made antiplatelet therapy the cornerstone of cardiovascular disease management. However, numerous patients will experience a recurrent atherothrombotic vascular event despite adequate antiplatelet therapy. Individual differences in the rate of platelet activation and reactivity markedly influence normal hemostasis and the pathological outcome of thrombosis. Such an individual variability is largely determined by environmental and genetic factors. These are known to either hamper platelets' response to agonists, and thereby mimic the pharmacological modulation of platelet function or mask therapy effect and sensitize platelets. In this article, we reviewed the antiplatelet mechanisms of aspirin and clopidogrel and the possible role of different polymorphisms, which may affect the efficacy of antiplatelet therapy. Heterogeneity in the way patients respond to aspirin and clopidogrel may in part reflect variation in cyclooxygenase (COX)-1, COX-2, glycoprotein (GP) Ib alpha, GP Ia/IIa, GP IIb/IIIa, UGT1A6*2, P2Y₁, P2Y₁₂, CYP2C9, CYP3A4 and CYP3A5 genotypes.